Free tool
FAERS Monitor: Absorica
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021951 or its brand name (Absorica, Isotretinoin). Reports on generic versions are filed under their own applications.
Reports
18,655
Serious
9,780
52% of reports
Hospitalization
1,464
Death reported
453
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- depression1,247
- pregnancy1,042
- exposure during pregnancy1,034
- abortion induced805
- product dose omission issue689
- headache680
- adverse drug reaction673
- dry skin672
- arthralgia658
- drug ineffective604
- suicidal ideation603
- mood altered534
- anxiety454
- off label use381
- lip dry367
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 124 |
| 2005 | 209 |
| 2006 | 355 |
| 2007 | 491 |
| 2008 | 766 |
| 2009 | 503 |
| 2010 | 492 |
| 2011 | 276 |
| 2012 | 383 |
| 2013 | 357 |
| 2014 | 345 |
| 2015 | 512 |
| 2016 | 769 |
| 2017 | 537 |
| 2018 | 616 |
| 2019 | 596 |
| 2020 | 864 |
| 2021 | 1,075 |
| 2022 | 1,580 |
| 2023 | 1,738 |
| 2024 | 2,348 |
| 2025 | 2,353 |
| 2026 | 1,366 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,035,504 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| abortion inducedSignal | 805 | 105.3 | 98.1 | 76,003 |
| pregnancySignal | 1,042 | 61.8 | 58.2 | 59,129 |
| lip drySignal | 367 | 47.4 | 42.8 | 15,970 |
| mood alteredSignal | 534 | 22.5 | 20.7 | 10,747 |
| exposure during pregnancySignal | 1,034 | 19.1 | 18.0 | 17,431 |
| adverse drug reactionSignal | 673 | 8.5 | 7.9 | 4,435 |
| suicidal ideationSignal | 603 | 7.5 | 6.9 | 3,365 |
| depressionSignal | 1,247 | 6.2 | 5.9 | 5,472 |
| dry skinSignal | 672 | 5.7 | 5.3 | 2,603 |
| product dose omission issueSignal | 689 | 2.6 | 2.5 | 712 |
| anxiety | 454 | 1.8 | 1.6 | 163 |
| arthralgia | 658 | 1.8 | 1.7 | 231 |
| headache | 680 | 1.2 | 1.1 | 28 |
| drug ineffective | 604 | 0.5 | 0.5 | 291 |
| off label use | 381 | 0.5 | 0.4 | 210 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.